Effect of the T-type channel blocker KYS-05090S in mouse models of acute and neuropathic pain

Pflugers Archiv European Journal of Physiology

Volumn 468, Issue 2, 2016, Pages 193-199

  M’Dahoma, Saïd ^a   Gadotti, Vinicius M ^a   Zhang, Fang Xiong ^a   Park, Byeongyeon ^c   Nam, Ji Hye ^c   Onnis, Valentina ^b   Balboni, Gianfranco ^b   Lee, Jae Yeol ^c   Zamponi, Gerald W ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c Kyung Hee University   (South Korea)

Author keywords

Calcium channels; KYS 05090S; Nociception; Pain; T type

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL CAV3.2; FORMALDEHYDE; KYS 05090S; UNCLASSIFIED DRUG; ANALGESIC AGENT; CACNA1H PROTEIN, MOUSE; CALCIUM CHANNEL T TYPE; KYS 05090; QUINAZOLINE DERIVATIVE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; HUMAN; HUMAN CELL; HYPERPOLARIZATION; MECHANICAL HYPERALGESIA; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; SCIATIC NERVE INJURY; TRANSIENT EXPRESSION; TRANSIENT TRANSFECTION; ACTION POTENTIAL; ACUTE PAIN; ANIMAL; C57BL MOUSE; HEK293 CELL LINE; MALE; METABOLISM; NEURALGIA; NOCICEPTION;

ACTION POTENTIALS; ACUTE PAIN; ANALGESICS; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEURALGIA; NOCICEPTION; QUINAZOLINES;

EID: 84954370328     PISSN: 00316768     EISSN: 14322013     Source Type: Journal    
DOI: 10.1007/s00424-015-1733-1     Document Type: Article

References (37)

1. Bladen C, Gadotti VM, Gunduz MG, Berger ND, Simsek R, Safak C, Zamponi GW (2015) 1,4-Dihydropyridine derivatives with T-type calcium channel blocking activity attenuate inflammatory and neuropathic pain. Pflugers Arch - Eur J Physiol 467:1237–1247. doi:10.1007/s00424-014-1566-3
2. Bladen C, McDaniel SW, Gadotti VM, Petrov RR, Berger ND, Diaz P, Zamponi GW (2015) Characterization of novel cannabinoid based T-type calcium channel blockers with analgesic effects. ACS Chem Neurosci 6:277–287. doi:10.1021/cn500206a
3. Bourinet E, Alloui A, Monteil A, Barrere C, Couette B, Poirot O, Pages A, McRory J, Snutch TP, Eschalier A et al (2005) Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J 24:315–324. doi:10.1038/sj.emboj.7600515
4. Cao XH, Byun HS, Chen SR, Pan HL (2011) Diabetic neuropathy enhances voltage-activated Ca2+ channel activity and its control by M4 muscarinic receptors in primary sensory neurons. J Neurochem 119:594–603. doi:10.1111/j.1471-4159.2011.07456.x
5. Cardenas CG, Del Mar LP, Scroggs RS (1995) Variation in serotonergic inhibition of calcium channel currents in four types of rat sensory neurons differentiated by membrane properties. J Neurophysiol 74:1870–1879
6. Chen CL, Broom DC, Liu Y, de Nooij JC, Li Z, Cen C, Samad OA, Jessell TM, Woolf CJ, Ma Q (2006) Runx1 determines nociceptive sensory neuron phenotype and is required for thermal and neuropathic pain. Neuron 49:365–377. doi:10.1016/j.neuron.2005.10.036
7. Choi S, Na HS, Kim J, Lee J, Lee S, Kim D, Park J, Chen CC, Campbell KP, Shin HS (2007) Attenuated pain responses in mice lacking Ca(V)3.2 T-type channels. Genes Brain Behav 6:425–431. doi:10.1111/j.1601-183X.2006.00268.x
8. De Petrocellis L, Moriello AS, Byun JS, Sohn JM, Lee JY, Vazquez-Romero A, Garrido M, Messeguer A, Zhang FX, Zamponi GW et al (2015) Inhibitory effect of positively charged triazine antagonists of prokinecitin receptors on the transient receptor vanilloid type-1 (TRPV1) channel. Pharmacol Res 99:362–369. doi:10.1016/j.phrs.2015.07.009
9. Dziegielewska B, Brautigan DL, Larner JM, Dziegielewski J (2014) T-type Ca2+ channel inhibition induces p53-dependent cell growth arrest and apoptosis through activation of p38-MAPK in colon cancer cells. Mol Cancer Res: MCR 12:348–358. doi:10.1158/1541-7786.MCR-13-0485
10. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpaa M, Hansson P, Jensen TS et al (2015) Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14:162–173. doi:10.1016/S1474-4422(14)70251-0
11. Francois A, Kerckhove N, Meleine M, Alloui A, Barrere C, Gelot A, Uebele VN, Renger JJ, Eschalier A, Ardid D et al (2013) State-dependent properties of a new T-type calcium channel blocker enhance Ca(V)3.2 selectivity and support analgesic effects. Pain 154:283–293. doi:10.1016/j.pain.2012.10.023
12. Francois A, Laffray S, Pizzoccaro A, Eschalier A, Bourinet E (2014) T-type calcium channels in chronic pain: mouse models and specific blockers. Pflugers Arch - Eur J Physiol 466:707–717. doi:10.1007/s00424-014-1484-4
13. Gadotti VM, Bladen C, Zhang FX, Chen L, Gündüz MG, Şimşek R, Şafak C, Zamponi GW (2015) Analgesic effect of a broad spectrum dihydropyridine inhibitor of voltage gated calcium channels. Pfulgers Arch
14. Gadotti VM, You H, Petrov RR, Berger ND, Diaz P, Zamponi GW (2013) Analgesic effect of a mixed T-type channel inhibitor/CB2 receptor agonist. Mol Pain 9:32. doi:10.1186/1744-8069-9-32
15. Gadotti VM, Zamponi GW (2011) Cellular prion protein protects from inflammatory and neuropathic pain. Mol Pain 7:59. doi:10.1186/1744-8069-7-59
16. Gavva NR, Tamir R, Qu Y, Klionsky L, Zhang TJ, Immke D, Wang J, Zhu D, Vanderah TW, Porreca F et al (2005) AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 313:474–484. doi:10.1124/jpet.104.079855
17. Gunthorpe MJ, Chizh BA (2009) Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug Discov Today 14:56–67. doi:10.1016/j.drudis.2008.11.005
18. Hildebrand ME, Smith PL, Bladen C, Eduljee C, Xie JY, Chen L, Fee-Maki M, Doering CJ, Mezeyova J, Zhu Y et al (2011) A novel slow-inactivation-specific ion channel modulator attenuates neuropathic pain. Pain 152:833–843. doi:10.1016/j.pain.2010.12.035
19. Honore P, Wismer CT, Mikusa J, Zhu CZ, Zhong C, Gauvin DM, Gomtsyan A, El Kouhen R, Lee CH, Marsh K et al (2005) A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharm Exp Ther 314:410–421. doi:10.1124/jpet.105.083915
20. Hylden JL, Wilcox GL (1980) Intrathecal morphine in mice: a new technique. Eur J Pharmacol 67:313–316
21. Jacus MO, Uebele VN, Renger JJ, Todorovic SM (2012) Presynaptic Cav3.2 channels regulate excitatory neurotransmission in nociceptive dorsal horn neurons. J Neurosci: Off J Soc Neurosci 32:9374–9382. doi:10.1523/JNEUROSCI.0068-12.2012
22. Jagodic MM, Pathirathna S, Joksovic PM, Lee W, Nelson MT, Naik AK, Su P, Jevtovic-Todorovic V, Todorovic SM (2008) Upregulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J Neurophysiol 99:3151–3156. doi:10.1152/jn.01031.2007
23. Jagodic MM, Pathirathna S, Nelson MT, Mancuso S, Joksovic PM, Rosenberg ER, Bayliss DA, Jevtovic-Todorovic V, Todorovic SM (2007) Cell-specific alterations of T-type calcium current in painful diabetic neuropathy enhance excitability of sensory neurons. J Neurosci: Off J Soc Neurosci 27:3305–3316. doi:10.1523/JNEUROSCI.4866-06.2007
24. Jensen TS, Madsen CS, Finnerup NB (2009) Pharmacology and treatment of neuropathic pains. Curr Opin Neurol 22:467–474. doi:10.1097/WCO.0b013e3283311e13
25. Jung SY, Lee SH, Kang HB, Park HA, Chang SK, Kim J, Choo DJ, Oh CR, Kim YD, Seo JH et al (2010) Antitumor activity of 3,4-dihydroquinazoline dihydrochloride in A549 xenograft nude mice. Bioorg Med Chem Lett 20:6633–6636. doi:10.1016/j.bmcl.2010.09.020
26. Kang HB, Rim HK, Park JY, Choi HW, Choi DL, Seo JH, Chung KS, Huh G, Kim J, Choo DJ et al (2012) In vivo evaluation of oral anti-tumoral effect of 3,4-dihydroquinazoline derivative on solid tumor. Bioorg Med Chem Lett 22:1198–1201. doi:10.1016/j.bmcl.2011.11.083
27. Malmberg AB, Basbaum AI (1998) Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain 76:215–222
28. Mantyh P (2013) Bone cancer pain: causes, consequences, and therapeutic opportunities. Pain 154(Suppl 1):S54–S62. doi:10.1016/j.pain.2013.07.044
29. Messinger RB, Naik AK, Jagodic MM, Nelson MT, Lee WY, Choe WJ, Orestes P, Latham JR, Todorovic SM, Jevtovic-Todorovic V (2009) In vivo silencing of the Ca(V)3.2 T-type calcium channels in sensory neurons alleviates hyperalgesia in rats with streptozocin-induced diabetic neuropathy. Pain 145:184–195. doi:10.1016/j.pain.2009.06.012
30. Petruska JC, Napaporn J, Johnson RD, Gu JG, Cooper BY (2000) Subclassified acutely dissociated cells of rat DRG: histochemistry and patterns of capsaicin-, proton-, and ATP-activated currents. J Neurophysiol 84:2365–2379
31. Rim HK, Cho S, Shin DH, Chung KS, Cho YW, Choi JH, Lee JY, Lee KT (2014) T-type Ca2+ channel blocker, KYS05090 induces autophagy and apoptosis in A549 cells through inhibiting glucose uptake. Molecules 19:9864–9875. doi:10.3390/molecules19079864
32. Snider WD, McMahon SB (1998) Tackling pain at the source: new ideas about nociceptors. Neuron 20:629–632
33. Stucky CL, Lewin GR (1999) Isolectin B(4)-positive and -negative nociceptors are functionally distinct. J Neurosci: Off J Soc Neurosci 19:6497–6505
34. Takahashi T, Aoki Y, Okubo K, Maeda Y, Sekiguchi F, Mitani K, Nishikawa H, Kawabata A (2010) Upregulation of Ca(v)3.2 T-type calcium channels targeted by endogenous hydrogen sulfide contributes to maintenance of neuropathic pain. Pain 150:183–191. doi:10.1016/j.pain.2010.04.022
35. Todorovic SM, Jevtovic-Todorovic V (2007) Regulation of T-type calcium channels in the peripheral pain pathway. Channels 1:238–245
36. Wen XJ, Xu SY, Chen ZX, Yang CX, Liang H, Li H (2010) The roles of T-type calcium channel in the development of neuropathic pain following chronic compression of rat dorsal root ganglia. Pharmacology 85:295–300. doi:10.1159/000276981
37. Yue J, Liu L, Liu Z, Shu B, Zhang Y (2013) Upregulation of T-type Ca2+ channels in primary sensory neurons in spinal nerve injury. Spine 38:463–470. doi:10.1097/BRS.0b013e318272fbf8